Modeling in process development can drastically reduce experiments, which is valuable for speed. However, even a small, single-digit percentage yield improvement in manufacturing provides a far greater long-term financial return. The gain is realized on every single batch produced throughout the product's entire commercial lifecycle, making it the most impactful area for modeling.

Don't start by pitching a full-scale, real-time digital twin. Instead, use historical data to build an offline model and demonstrate concrete business value, such as a potential yield increase. This proven ROI makes it much easier to get executive backup and funding for the more expensive live implementation.

For startups adopting AI, the most effective starting point is not a massive overhaul. Instead, focus on a single, high-value process unit like a bioreactor. Use its clean, organized data to apply simple predictive models, demonstrate measurable ROI, and build organizational confidence before expanding.

By training on multi-scale data from lab, pilot, and production runs, AI can predict how parameters like mixing and oxygen transfer will change at larger volumes. This enables teams to proactively adjust processes, moving from 'hoping' a process scales to 'knowing' it will.

The acceptable ranges used in GMP manufacturing are typically defined by mathematical models built during process validation. Adopting a digital twin isn't introducing a foreign concept; it's simply deploying the same type of model in real-time with a human in the loop, rather than using a static, one-time calculation.

The future of bioprocess development involves using AI on high-throughput data for predictive modeling. This, combined with in silico simulations (digital twins), will allow scientists to understand underlying biological mechanisms, not just identify optimal conditions, dramatically accelerating optimization.

Instead of aiming for a massive, all-encompassing digital twin, identify a critical business bottleneck first. Build a focused, end-to-end offline model to prove its value. Only after demonstrating a clear return on investment should you scale it into a real-time, fully integrated system. This 'moonshot before Mars' approach minimizes risk and builds momentum.

Many assume vast amounts of data are necessary for a digital twin. In reality, process validation data combined with a handful of manufacturing trends is often sufficient. The focus should be on data quality and its relevance to a specific business decision, not sheer quantity. This approach makes powerful modeling accessible much earlier.

Instead of immediately building complex models for a single problematic unit operation, start with simple linear models that connect the entire process. This holistic view reveals which parameters truly impact the final drug substance, allowing you to focus resources on building complex models only where they are most critical.